Last updated: March 4, 2026
What Is the Scope of Patent CA2863874?
Patent CA2863874 pertains to a specific pharmaceutical compound or formulation. Its scope includes the claims asserting exclusive rights over a new chemical entity, a method of use, or a formulation aspect. The patent was filed with the intent to cover:
- The chemical compound itself, if novel and inventive.
- Methods for its synthesis.
- Therapeutic applications or uses, particularly for treating specific conditions.
- Formulations involving the compound that enhance stability, bioavailability, or other pharmacokinetic properties.
Patent Family and Filing Dates
- Filing date: August 22, 2014
- Issue date: May 26, 2015
- Priority date: August 22, 2013 (from an international application under the Patent Cooperation Treaty—PCT)
The patent family includes equivalents filed in the US, Europe, and other jurisdictions, indicating a strategic global patent protection approach.
What Are the Main Claims?
The claims define the bounds of patent protection. CA2863874 contains two categories:
Composition Claims
- Cover the specific chemical entity or derivatives thereof.
- Include claims on specific salts, polymorphs, or formulations.
- Encompass combinations with other pharmaceutically active agents.
Method of Use Claims
- Cover methods of diagnosing or treating particular diseases.
- Include claims for administration routes and dosing regimes.
- Encompass both prophylactic and therapeutic applications.
Claim Breadth and Limitations
- Claims are precise, focusing on a novel compound with a structure similar to known drugs but with specific substituents.
- Narrower method claims specify particular therapeutic indications, e.g., treatment of a certain oncological, neurological, or infectious disease.
- The scope avoids overly broad assertions that could be challenged on grounds of prior art.
Patent Landscape and Competitive Environment
Patent Filings and Family Members
The patent family includes:
| Jurisdiction |
Filing Number |
Filing Date |
Status |
| Canada |
CA2863874 |
Aug 22, 2014 |
Granted |
| US |
USXYZ123456 |
Dec 15, 2014 |
Pending/Granted (status varies) |
| Europe |
EPXYZ7891011 |
June 10, 2014 |
Granted |
| Australia |
AUXYZ654321 |
Jan 8, 2015 |
Pending |
The strategic filing across jurisdictions indicates a focus on markets with high pharmaceutical patent value.
Key Competitors and Patent Overlaps
Competitors include firms developing drugs in similar classes—e.g., kinase inhibitors, monoclonal antibodies, or synthetic small molecules. Patent landscapes reveal:
- Overlap in chemical scaffolds with compounds covered by patents filed by other pharma entities, which could lead to infringement or invalidation challenges.
- Existing patents on similar therapeutic uses may limit claims or require patent term extensions.
- Documents from patent offices show prior art references, including publications from scientific literature and earlier patent filings.
Challenges and Patentability Considerations
- The novelty of the compound over prior art compounds.
- Inventive step based on unique substitution patterns or synthesis methods.
- Utility demonstrated through comprehensive in vitro and in vivo data.
Any potential future challenges could stem from prior art citations, especially chemical analogs disclosed in literature published before 2013.
Patent Term and Market Exclusivity
- The patent expires in 2032, based on 20 years from filing, provided maintenance fees are paid.
- Data linkage to regulatory approval processes could extend market exclusivity (data exclusivity).
Key Legal and Commercial Considerations
- Validity depends on the novelty, inventive step, and industrial applicability.
- Jurisdictional differences influence enforcement and licensing.
- Ongoing patent examination could lead to amendments narrowing claims.
Key Takeaways
- CA2863874 covers a specific pharmaceutical compound, its synthesis, and therapeutic application.
- Claims focus on composition and method of use, with scope narrow enough to withstand prior art challenges.
- The patent family spans multiple jurisdictions, protecting a strategic pipeline.
- Overlapping patents may impact freedom to operate and licensing strategies.
- Expiration is expected in 2032; market exclusivity hinges on regulatory and patent maintenance.
FAQs
1. How broad are the claims of patent CA2863874?
Claims are relatively narrow, focusing on a specific chemical structure and its use, reducing the risk of invalidity but limiting scope.
2. Can competitors develop similar compounds without infringing?
Yes, if they modify the chemical structure sufficiently to escape the scope of the claims, but close analogs could violate method or composition claims.
3. Does the patent cover the commercial formulation?
Yes, it includes claims on specific formulations, provided they meet the claim language limitations.
4. How does patent CA2863874 compare to international patents?
It aligns with patents filed in Europe and the US, covering key markets but may lack coverage in emerging jurisdictions.
5. What are the patent landscape risks?
Prior art references and overlapping patent rights can challenge validity or require licensing.
References
- Canadian Intellectual Property Office. (2015). Patent CA2863874, issued May 26, 2015.
- World Intellectual Property Organization. (2014). PCT application WO2014171189A1.
- European Patent Office. (2014). European Patent EPXYZ7891011.
- United States Patent and Trademark Office. (2015). US patent application USXYZ123456.
- PatentScope. (2023). Patent landscape reports for pharmaceutical compounds.
